The academic affiliation between the Icahn School of Medicine at Mount Sinai (ISMMS) and Rensselaer Polytechnic Institute (RPI) fosters educational and research collaborations and stimulates the development of new technologies to radically improve the diagnosis and treatment of human disease.
Both schools bring unique strengths to this partnership. Mount Sinai is a leader in biomedical research and patient care, while RPI excels in engineering and computational sciences. The relationship exists to offer cross-disciplinary education that enriches research at all levels, and to create new technologies that generate new intellectual property. As a result, the pace of innovation and entrepreneurship across the health sciences is accelerated.
Collaborative Center for Research Innovation and Entrepreneurship
The Mount Sinai and Rensselaer Collaborative Center for Research Innovation and Entrepreneurship is the hub for these joint efforts, with the Mount Sinai Institute of Technology (MSIT) functioning as the primary partnership locus at Mount Sinai. Complementary research programs involving Mount Sinai and RPI investigators address a broad range of conditions in such diverse areas as neuroscience and neurological diseases, genomics, imaging, orthopedics, cancer, and cardiovascular disease.
We aim to collaborate on scientific and clinical targets that capitalize on each institution's areas of specialization. We are exploring joint funding in research programs to support our work in precision medicine, drug discovery, stem cell biology, robotics and robotic surgery, novel imaging techniques, cellular engineering, and computational neurobiology.
In May 2014, the Rensselaer-Mount Sinai Collaborative Research Projects program selected seven collaborative project proposals for jointly sponsored pilot funding in cancer, vascular disease, hepatitis, musculoskeletal disease, influenza, and drug abuse. The May 2014 Symposium on Regenerative Medicine conference brought together Mount Sinai and RPI investigators to share their work and discuss future collaborations.